Valuation: Ovid Therapeutics Inc.

Market Cap 47Cr 41Cr 38Cr 35Cr 66Cr 4.5TCr 68Cr 455.38Cr 178.6Cr 2.21TCr 176.61Cr 172.75Cr 7.63TCr P/E 2026 *
-5.22x
P/E 2027 * -4.73x
Enterprise Value 47Cr 41Cr 38Cr 35Cr 66Cr 4.5TCr 68Cr 455.38Cr 178.6Cr 2.21TCr 176.61Cr 172.75Cr 7.63TCr EV / Sales 2026 *
4,375x
EV / Sales 2027 * 2,822x
Free-Float
92.99%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day-2.78%
1 week-6.32%
Current month-9.11%
1 month+8.19%
3 months-12.37%
6 months+48.18%
Current year+50.00%
1 week 2.39
Extreme 2.39
2.82
1 month 2.19
Extreme 2.19
2.84
Current year 1.36
Extreme 1.36
3.1
1 year 0.36
Extreme 0.36
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07Other

Chief Financial Officer

4,50,625 0.2414%
06/07Free

Chief Financial Officer

50,000 0.0268%
15/06Free

Director

1,30,000 0.0697%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-6.32%+516.02%-28.30% 47Cr
-2.48%-3.13%+55.85%+89.65% 5.49TCr
-0.55%-6.57%+55.85%+128.31% 5.46TCr
-5.55%-2.78%+6.43%+417.12% 2.51TCr
-1.66%-4.27%-18.99%-17.89% 2.31TCr
-1.69%-0.64%+40.04%-0.48% 1.99TCr
+1.87%+4.16%+38.74%-26.42% 1.75TCr
-2.72%-0.60%+187.08%+351.91% 1.65TCr
-2.42%+1.00%+48.24%+635.77% 1.57TCr
-1.16%+0.50%+22.44%+188.42% 1.42TCr
Average -1.96%-1.37%+95.17%+173.81% 2.42TCr
Weighted average by Cap. -1.88%-1.57%+48.43%+165.17%

Financials

2026 *2027 *
Net sales 1L 94.29T 87.33T 80.35T 2L 1.03Cr 2L 10.41L 4L 50.53L 4L 4L 1.74Cr 2L 1L 1L 1L 2L 1.6Cr 2L 16.14L 6L 78.34L 6L 6L 2.71Cr
Net income -7.71Cr -6.76Cr -6.27Cr -5.76Cr -11Cr -738.15Cr -11Cr -75Cr -29Cr -362.49Cr -29Cr -28Cr -1.25TCr -8.98Cr -7.88Cr -7.3Cr -6.72Cr -13Cr -859.88Cr -13Cr -87Cr -34Cr -422.27Cr -34Cr -33Cr -1.46TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
14/26/14 $2.445 -2.98% 7,43,678
10/26/10 $2.520 -3.08% 13,94,301
09/26/09 $2.600 -4.76% 18,60,058
08/26/08 $2.730 -1.09% 30,27,379
07/26/07 $2.760 +5.75% 33,12,954
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.520USD
Average target price
5.471USD
Spread / Average Target
+117.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock